High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
Top Cited Papers
Open Access
- 16 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 26 (11), 2353-2359
- https://doi.org/10.1038/leu.2012.105
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with SorafenibTransplantation and Cellular Therapy, 2011
- Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3‐internal tandem duplication positive acute myeloid LeukaemiaBritish Journal of Haematology, 2011
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood, 2011
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoBlood, 2011
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasHaematologica, 2010
- Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantationBlood, 2010
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasLeukemia, 2010
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood, 2006
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003